New Strong Sell Stocks for January 7th

Zacks added 89bio (ETNB), Altice USA (ATUS) and Ashland (ASH) to its Zacks Rank #5 (Strong Sell) list after substantial downward revisions to consensus earnings estimates over the past 60 days: ETNB -38.8%, ATUS -250%, and ASH -16.2%. The moves signal a materially weaker near‑term earnings outlook and negative analyst sentiment for these companies—89bio in biotech, Altice in broadband/video services, and Ashland in specialty additives—which could create downside pressure on their share prices as investors reassess fundamentals and guidance.

Analysis

Market structure: The Zacks downgrades concentrate near-term pain on ATUS (highly negative) and to a lesser extent ASH; direct losers are equity holders and high-yield creditors of Altice (higher default/refinancing risk), while broadband peers (e.g., CMCSA, CHTR) could see temporary spread compression if investors rotate out of idiosyncratic credit risk into higher-quality cable assets. For biotech ETNB the market signals demand for de-risked assets is drying up—expect higher implied volatility and bid-side weakness in small-cap biotech, pressuring funding rounds and secondary offerings.

Risk assessment: Tail risks include ATUS covenant breaches or opportunistic debt acceleration (low-probability but high-impact) over the next 3–12 months, and a binary clinical failure for ETNB that could wipe equity value within 6–12 months. Short-term (days–weeks) risks: volatility spikes, widening credit spreads; medium-term (months): earnings revisions and potential asset sales; long-term (quarters–years): structural shifts if Altice loses market share or Ashland faces raw-material margin squeeze.

Trade implications: Tactical trades include short-tilt on ATUS via 3-month put spreads (buy ATM, sell 25–30% OTM) sized to 2–4% portfolio risk, and a conservative 1–2% long in ASH on >10% pullback targeting 15–25% recovery over 6–12 months. Avoid naked short ETNB equity; consider capped downside via buying 12-month LEAPS calls (size 0.5% notional) as optionality if clinical readouts are due within 9–12 months.

Contrarian angles: The consensus may over-penalize ETNB’s optional upside—if upcoming trial milestones exist within 6–12 months, cheap LEAPS or buy-write structures can exploit asymmetric payoff. Conversely ATUS may be underpriced if management can refinance or sell assets; monitor covenant dates and upcoming guidance (next 30–90 days)—if no near-term liquidity cliff, scale back short exposure to avoid squeeze risk.

Key Decisions for Investors

• Establish a short-biased position in Altice USA (ATUS): allocate 2–4% of portfolio risk via a 3-month put spread (buy ATM put, sell a 25–30% OTM put) to limit capital while targeting a 30–50% downside move within 3–6 months; cut if ATUS rallies >20% from entry or if credit spreads tighten by >200bps.
• Reduce cyclical exposure to small-cap biotech (ETNB) and avoid naked shorts; instead allocate 0.5% notional to 12-month LEAPS calls on ETNB to capture binary upside ahead of any clinical readouts, exit or roll down if no positive data within 12 months or implied vol drops >40%.
• Build a selective long in Ashland (ASH) sized 1.5–3% if shares decline >10% from current levels; target 15–25% upside over 6–12 months driven by estimate reversion, place stop-loss at -12% and reassess after next quarter earnings.
• Monitor Altice debt maturities, covenant language, and upcoming guidance over the next 30–90 days; if a material covenant or refinancing risk is disclosed, increase short exposure to ATUS via additional put spreads or add CDS exposure where available.